???pagination.result.count???
???pagination.result.page???
1
Block of Kcnk3 by protons. Evidence that 2-P-domain potassium channel subunits function as homodimers. , Lopes CM., J Biol Chem. July 6, 2001; 276 (27): 24449-52.
Inhibition of TASK-1 potassium channel by phospholipase C. , Czirják G., Am J Physiol Cell Physiol. August 1, 2001; 281 (2): C700-8.
The acid-sensitive potassium channel TASK-1 in rat cardiac muscle. , Putzke C., Cardiovasc Res. July 1, 2007; 75 (1): 59-68.
Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney. , Wolff NA., Nephrol Dial Transplant. September 1, 2007; 22 (9): 2497-503.
The human cardiac K2P3.1 ( TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone. , Gierten J., Naunyn Schmiedebergs Arch Pharmacol. March 1, 2010; 381 (3): 261-70.
TASK-1 channels may modulate action potential duration of human atrial cardiomyocytes. , Limberg SH., Cell Physiol Biochem. January 1, 2011; 28 (4): 613-24.
Carvedilol targets human K2P 3.1 ( TASK1) K+ leak channels. , Staudacher K., Br J Pharmacol. July 1, 2011; 163 (5): 1099-110.
TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation. , Seyler C., Br J Pharmacol. March 1, 2012; 165 (5): 1467-75.
Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels. , Schmidt C., Eur J Pharmacol. December 5, 2013; 721 (1-3): 237-48.
Gain-of-function mutation in TASK-4 channels and severe cardiac conduction disorder. , Friedrich C., EMBO Mol Med. July 1, 2014; 6 (7): 937-51.
Cloning, functional characterization, and remodeling of K2P3.1 ( TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure. , Schmidt C., Heart Rhythm. October 1, 2014; 11 (10): 1798-805.